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Chapter 1: Leishmanisis: The world’s second deadliest parasite 
Leishmaniasis is the world’s second deadliest parasite with an estimated 1.3 million new 
cases every year and death totals that range from 20,000-30,000 per year
1
. It is a vector-borne 
disease that is typically spread by the bite of the female phlebotomine sandfly.  The females 
require blood for their eggs and they acquire and transmit the disease when they feed
2
. Human 
infection is caused by approximately 21 to 30 different species of sandflies which are endemic to 
intertropical and temperate regions of the world
2
. 
The leishmania parasite can be found in two different stages: The promastigote stage 
(infective stage) and the amastigote stage (proliferative tissue stage). These stages of the parasitic 
life cycle are illustrated in Figure 1.   When an infected sandfly takes a bloodmeal it injects 
Figure 1 
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promastigotes into the blood which are then phagocytized by macrophages or other mononuclear 
phagocytotic cells. Once the parasite has been phagocytized it transforms into the amastigote 
which then proliferates within the phagocytotic cells. Since the amastigotes replicate continually 
the phagocytotic cells usually undergo cellular lysis which releases the amastigotes into the 
blood stream which are then phagocytized or infect other cells. When a sandfly takes a 
bloodmeal from an infected human it ingests infected macrophages which then release the 
amastigotes into the sandfly. Within the sandfly the amastigotes transform back into the 
promastigote where they can then be transmitted back to a human after another bloodmeal
3
.  
It is possible for an infected host to never develop the disease; however, leishmaniasis 
can present itself with symptoms in three different forms: cutaneous, mucocutaneous, and 
visceral leishmaniasis.  
 Cutaneous leishmaniasis (CL) is the most common form of the disease and causes skin 
lesions, typically in the form of an ulcer. These lesions can develop as quickly as several 
weeks or take years to appear. The ulcers are non-lethal however they can becomes infected 
which may lead to discomfort, life-long scars other medical problems
1,4
. 
 Mucocutaneous leishmaniasis (ML) is a result of leaving cutaneous leishmaniasis untreated 
which allows the disease to spread to the naso-oropharyngeal mucosa (mucous membranes of 
the nose, mouth, and throat). The symptoms involve bleeding of the infected area which can 
then become ulcerous leading to ulcerative destruction
1,4
. 
 Visceral leishmaniasis (VL, a.k.a. kala-azar) is the fatal form of leishmaniasis when it is left 
untreated. Visceral leishmaniasis is found in internal organs and has a list of symptoms that 
include weights loss, fever, hepatomegaly and /or splenomegaly, pancytopenia. Both the 
direct effects and secondary effects, such as hemorrhage or secondary infection, are fatal
1,4
.  
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Figure 2. The maps show the geographical distribution 
of different forms of leishmaniasis in the world. The 
map above shows the distribution if visceral 
leishmaniasis. The map to the right shows the 
distribution of cutaneous and mucocutaneous 
leishmaniasis. Adapted from Reference 5. 
After looking at  maps depicting the worldwide distribution of leishmaniasis (Figure 2
5
), 
it is fairly obvious why leishmaniasis is one of the seventeen prioritized Neglected Tropical  
 
diseases (NTD) . The CDC defines a NTD as any group of parasitic and bacterial diseases that 
cause substantial illness for more than one billion people globally
6
 and leishmaniasis falls into 
this category. NTD’s affect the world’s poorest countries and people; making diagnostics, 
treatments, administration, and logistics more difficult. Long-term monitoring of the disease is 
also a major problem. It is important to monitor for relapse or recrudescence in patients who 
have overcome the disease because drug resistant strains are beginning to appear in areas such as 
Bihari-India and south-east Nepal. Patients with more severe cases of leishmaniasis require more 
intensive therapies which are very difficult due to administration (intravenous injection), and 
expensive in third world countries.  Leishmaniasis is also one of the NTD’s that has limitations 
on the large scale use of the existing therapies and treatment methods
7
.  
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Current Therapies 
Antimonials 
  
 
Pentavalent antimonial drugs have been the first-line of defense against leishmaniasis 
worldwide for over 75 years. Pentostam® and Glucantime® (seen above) are the two current 
drugs that are approved for clinical use. These drugs are administered intravenously at 20 
mg/kg/day up to 1275 mg over 20 or 30 days. The trivalent antimonial is the pharmacophore that 
kills the parasites through alteration of their biopathways. Side effects of the antimonials include 
nausea, diarrhea, vomiting, malaise, myalgia, and anorexia. The cure rate for these drugs is 
roughly 85-95% except in countries that have resistant strains to these drugs
8
. 
 
Amphotericin B 
 
     Sodium Stibogluconate (Pentostam)          Glucantime 
Amphotericin B 
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 Amphotericin B is a macrolide polyene that is used commonly in locations where 
antimonial resistance is prevalent. The drug is encapsulated in a liposome and then administered 
intravenously at 7-20mg/kg/day for up to 20 days. Amphotericin B binds to membrane ergosterol 
which results in pore formation and ultimately parasite cell lysis. The major side effect of this 
drug is renal toxicity, which can be reduced through the use of a liposomal derivative of this 
drug. However, both of these drugs are expensive which limits their use in developing countries
8
.  
 
Miltefosine 
 
  
 
Miltefosine is one of the newest drugs on the market and is derived from cancer 
therapeutics. This drug is thought to alter multiple pathways within the parasite such as signal 
transduction and glycosylphosphatidylinositol anchor (GPI) synthesis. This was the first 
approved anti-leishmanial drug that could be administered orally,  which has led to extremely 
high cure rates in both CL and VL at 100-150mg/day for 28 day doses. Side effects include 
nausea and vomiting, but overall are quite mild
8
.  
 
 
 
Miltefosine 
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Natural Products as Drugs 
It becomes apparent after looking at the current antileishmanial therapies  that new drugs 
are needed that are less toxic and expensive. While the use of high-throughput screening with 
large combinatorial libraries has gained popularity in recent years, natural products, or their 
derivatives, are still the major source of leads as drug molecules
9
. It can be seen in Figure 3 that 
only 36% of new approved small molecule drugs since 1981 are purely synthetic. 64% of new 
small molecule drugs since 1981 are natural products or derived from these species. From 1981 
to 2010 only 14 antiparasitic compounds have been approved as drugs and 9 of them were 
natural products or related derivatives
9
. Since a majority of these compounds are natural products 
it emphasizes the importance to continue utilizing natural sources as a means of discovery for 
novel antiparasitic secondary metabolites.  
 
 
Figure 3 Newman, D. J.; Cragg, G. M. J. Nat. Prod. 2012, 75, 311–335. 
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Chapter 2: The Discovery, biological evaluation, and structure activity relationship study 
of Pentalinonsterol 
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The Discovery and Chemical Analysis of Pentalinonsterol 
Ancient Mayans utilized the roots of Pentalinon Adrieuxii, which is native to the Yucatan 
Peninsula in Mexico, as a means of treating leishmaniasis. The internal parts of the roots were 
applied to the lesions on the body and were 
reapplied daily until visible healing had 
occurred. Previous biological evaluations of 
this plant led to the discovery of other natural 
products with antileishmanial activity, which  
was of interest in the Kinghorn lab, one of 
our collaborators on this project at The Ohio 
State University
10
. The Kinghorn group utilized bioassay guided fractionation against the 
protozoa of L. mexicana in order to isolate the most active components of the Pentalinon 
Adrieuxii roots. During the course of isolation, the root material was extracted and fractionated 
using solvents of varying polarity. The hexanes extract was found to be most active of the 
partitions. It was also noted that topical treatment of infected mice ear cells with the hexanes 
extract of the P. Adrieuxii roots showed inhibition of leishmanial growth which can be seen 
below in figure 6. 
The control consisted 
of L. Mexicana 
infested macrophages 
of the mouse ear cells 
and it can be seen in 
the PARE treated 
Figure 5 Air dried Pentalinon Adrieuxii 
roots 
 
Figure 4 The effect of topical application of the hexane extract of 
the P. andrieuxii roots against L. Mexicana. 
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cells that the viral load has decreased. The PARE is the hexane extract which contains 
pentalinonsterol (PEN).  Isolation and purification of the hexanes extract resulted in the 
identification of 20 compounds which were subsequently submitted for testing against L. 
Mexicana. Figure 5 portrays the structures of the most active compounds from the screen. Table 
1 contains the names and activities of the respective compounds against both the amastigote and 
promastigote forms of the parasite with pentostam as the positive control. 
 
 
 
 
Table 1 In vitro antileishmanial activities of compounds isolated from the roots of 
Pentalinon Andrieuxii
10
 
 
Figure 6 Structures of the most active compounds isolated from the roots of Pentalinon 
Andrieuxii. 
 
17 
 
It is also important to note that these compounds were also tested against uninfected mouse cells 
lines and showed no cytotoxicity, demonstrating a lack of toxicity to healthy tissue and 
selectivity for infected cells lines
10
. Analysis of Table 1 shows us that, against amastigotes, 
compound 4 is the most active with an IC50 of 30 nM
10
. This compound is simply an oxidized 
derivative of cholesterol. All of the active compounds tested had similar activity to the pentostam 
control except compound 7. This is important because these compounds have similar toxicity 
while being selective towards the infected cells. Examination of the antileishmanial activities and 
chemical structures of the isolated compounds provided a preliminary hypothesis for which 
chemical moieties are required for activity (pharmacophore determination). For example, the 
only difference between compounds 1 and 7 is the oxidation of the A-ring and based on the 
dramatic difference in potency, it can be hypothesized that the A-ring α,β-unsaturated ketone is 
important. However, while compound 7 lacks the A-ring oxidation, it is still relatively active. 
This is likely due to the presence of the same C17 side chain that is found in pentalinonsterol 
(PEN). Pentalinonsterol was one of two novel compounds isolated by the Kinghorn lab during 
this study, although it was the only one found to possess antileishmanial activity
10
. 
Unfortunately, only 1.2 mg of pure pentalinonsterol could be isolated from 900g of dried P. 
Adrieuxii roots, thus limiting biological studies of this compound.  Based on the limited 
availability of the compound, structural novelty, and predicted relative ease of synthetic access to 
pentalinonsterol, a synthetic approach was developed in order to generate more pentalinonsterol 
for biological and mechanism of action studies and to determine the structure activity 
relationship of the chemical moieties of this natural product.  
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The Semi-Synthesis and optimization of Pentalinonsterol 
 Based on the need for a synthetic route to pentalinonsterol, a relatively simple synthetic 
scheme was devised starting from an inexpensive commercially available sterol (pregnenolone, 
$4.56/gram). The key reaction was proposed to be an enolate alkylation reaction which would 
install a prenyl unit onto the methyl ketone at the C17 position. The scheme below depicts the 
two closely related synthetic schemes that have been used to prepare pentalinonsterol. In Scheme 
1, the initially reported procedures and yields of Dr. Dalia Abdelhamid, a former graduate 
student in the Fuchs lab, are enclosed in black boxes. Dr. Abdelhamid’s route to pentalinonsterol 
provided the natural product in 25% overall yield from the starting pregnenolone
11
 and 
demonstrated that the methyl ketone could be efficiently functionalized. Optimization of the 
synthetic route in collaboration with Mr. Andrew Huntsman, another undergraduate researcher in 
the Fuchs lab, led to the improved conditions reported in red. The optimized synthetic route was 
designed to increase the overall efficiency of the synthesis by increasing overall reaction yields 
as well as using less expensive reagents. Notably, this route increased the overall yield to nearly 
50% and eliminated the use of the expensive and somewhat reactive Tebbe reagent. 
 
 
 
 
 
 
 
 
Scheme 1 The first and second generations of the semi-synthesis of pentalinonsterol 
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In both routes, the synthesis began with protection of the C3 alcohol of pregnenolone. 
This protection reaction was run under the same conditions in both cases, although upon 
repeating the reaction on larger scale a 94% yield of the protected pregnenolone could be 
obtained as a precipitate. In these syntheses, TBSCl is used as the protecting agent instead of the 
more commonly employed acetate group in order to provide increased stability in the subsequent 
alkylation reaction.  
Precedented procedure for the alkylation on the C21 position of pregnenolone through the 
kinetic enolate formation was reported by Hanson et. al.
12
. We chose to use strong, sterically 
hindered bases in order to generate the kinetic enolate which was then alkylated upon addition of 
the 3,3-dimethylallyl bromide. Dr. Abdelhamid used LDA to form the kinetic enolate and HMPA 
as a cosolvent to make a more reactive “naked” enolate. Attempts to reproduce this result for the 
revised synthesis failed to produce the same yield of product.  As an alternative, LiTMP was 
utilized in place of LDA and HMPA in order to achieve our highest yield of 67%. Utilization of 
LiTMP allowed us to avoid the distillation and use of the highly carcinogenic HMPA. Another 
key change to Dr. Abdelhamid’s procedure was a change in the purification technique. Due to 
the lipophilicity of the alkylated product, she employed gravity columns with very non-polar 
systems. In order to optimize this process, we found that a gradient column run from 0 EtOAc: 0 
DCM: 100 Hexanes up to 2:2:96 allowed us to separate the desired monoalkylated product from 
the undesired dialkylated product as well as the starting material while using flash column 
chromatography methods. Ultimately, variations in the yields of these alkylation reactions were 
observed, and were attributed to the quality of the reagents, the scale on which the reaction was 
run, and attention to laboratory techniques for the handling of air- (or water-) sensitive materials.   
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With the alkylation adduct in hand, the next task involved the olefination of the carbonyl 
in the C17 side chain. Dr. Abdelhamid used the highly reactive Tebbe reagent in order to effect 
olefination of this ketone. Although the yield of the reaction was acceptable, the Tebbe reagent is 
rather expensive ($58.61/gram) and was found to degrade rapidly upon storage. In addition, 
workup of this reaction resulted in an emulsion which made the extraction extremely time 
consuming. In the revised synthesis, it was found that the olefinated product 5 could be 
effectively generated through Wittig olefination, which is much cheaper than the Tebbe reagent. 
This modification required the use of excess Wittig reagent ($1.01/gram), but provided much 
higher yields of the desired product. 
After the fully functionalized C17 side chain had been installed, all that remained to do 
was the deprotection of the TBS ether and subsequent oxidation of the sterol A-ring. The TBAF 
deprotection of the alcohol was done as previously reported with similar yield. Dr. Abdelhamid 
initially employed a well-precedented Oppenauer oxidation with cyclohexanone as the co-
oxidant in an attempt to generate the natural product. She reported, however, that under these 
conditions a mixture of oxidized products, including the ketone product in which the B-ring 
olefin did not undergo isomerization to the α,β-unsaturated ketone, were generated. Based on this 
result, she switched to the higher boiling 1-methyl-4-piperidone which had previously been 
reported by Keana et. al
13
. During optimization it was determined that cyclohexanone could be 
used effectively in this transformation. We believe that the isomerization issue was avoided 
because the reaction was run overnight. This increased reaction time would allow more time for 
formation of the thermodynamic product. Employing the optimized synthetic sequence, 
pentalinonsterol was generated on gram scale. 
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Proposed Mechanisms of Action of Pentalinonsterol 
 As anticipated, the synthesis of pentalinonsterol has facilitated further biological testing 
of this natural product. In the original isolation paper, the authors demonstrated that the natural 
product had promising antileishmanial activity, but the exact nature of this activity was 
unknown. It was postulated that the sterol compounds may act as antagonists of endogenous 
biosynthetic pathways for leishmanial sterols
10
, although other hypotheses also included 
interaction with or destabilization of the membrane and effects on the host immune system. 
Biological testing performed by the Parinandi lab at the Ohio State University has shown 
that treatment of L. donovani promastigotes with PEN led to a decrease in the saturated and 
unsaturated fatty acid composition in the lipids which can be seen in figure 7. This is proposed 
to effect phospholipases A1 and A2 via a hydrolysis and metabolomics breakdown of the fatty 
acid esters in the membrane of the parasites
14
. Alteration of the fatty acid content in the lipid 
bilayer could make the membrane more porous and result in leaking of cellular components, 
resulting in cell death. PEN has potential efficacy against multiple Leishmania species since the 
fatty acid content among all of the known species of Leishmania is consistent
14
.  
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Figure 7 Fatty acid disruption in Leishmania donovani promastigotes by sPEN.  Fatty 
acid composition of L. donovani promastigotes treated with or without sPEN (5 and 10 
µg/ml) for 12h. Fatty acids in total membrane lipids were derivatized into methyl 
esters by alkaline methanolysis and analyzed by gas chromatography-mass 
spectrometry. C16:0 = palmitic acid; C18:0 = stearic acid; C18:1 = oleic acid; C18:2 = 
linoleic acid; C20:4 = arachidonic acid; C22:6 = docosahexaenoic acid. Data are 
presented as mean of three replicates ±S.D. Statistical significance with respect to 0 
µg/ml sPEN is presented as *p < 0.05
14
. 
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The Satoskar lab has also reported PEN to be more effective at treating intracellular 
amastigotes than promastigotes. This is ideal because the infected hosts contain the amastigote 
form of the leishmaniasis which is the form that is actively being treated. It is also important to 
remember that PEN is not cytotoxic towards healthy host macrophages making this a clinically 
relevant drug. Due to PEN’s poor water solubility due to its extremely high lipophilicity the 
Ainsley lab at the University of North Carolina has a liposomal formulation of PEN that allows it 
to be administered and used for in vivo testing. When using liposomal PEN (lPEN) to treat 
infected mice, a significantly lower parasite load was seen in the liver, spleen, and bone marrow 
(figure 8).  
 
 
 
Figure 8 Liposomal sPEN treatment renders protection against L. donovani infected mice. (A) 
Liver (B) spleen and (C) bone marrow parasite loads in L. donovani infected BALB/c mice 
treated with either PBS, empty liposomes, sPEN loaded liposomes (50 µg or 2.5 mg per kg 
body weight), or sodium stibogluconate SSG (70 mg per kg body weight). Parasite burdens in 
spleen and liver were expressed as mean LDU; parasite burden in bone marrow was 
expressed as number of amastigotes per 200 macrophages.  Data is presented as mean ± SE. 
These data are mean values from four or five individual mice per group at each time point in 
three independent experiments with similar results. Significance is presented as *** p < 
0.001
14
. 
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In conjunction with parasite load reduction, it has been observed that PEN may also act 
as an adjuvant. Not only does PEN reduce parasite load, but it also is thought to enhance the 
lympho-proliferative responses in the host. 
After treatment with lPEN, infected mice 
showed an increase in T cell proliferation. 
This is important because active VL impairs 
the immune response preventimg the T cells 
from responding to the infection properly. 
Treatment of the mice with lPEN also 
increased the production of IFN-γ14 which is 
a cytokine that is responsible for inate and 
adaptive immunity against infections (figure 
9). It has been proven that IFN-γ is 
responsible for clearance of leishmaniasis 
from infected cells
15
 which is why it is beneficial that PEN can increase these levels. In 
conclusion, PEN is capable of killing leishmaniasis via two mechanisms, alteration of the fatty 
acid content in the parasites lipid bilayer and enhancing a protecting immune respone by 
increasing IFN-γ levels leads to eradication of the leishmaniasis14.  
  
  
Figure 9 IFN-γ levels in infected mice cells 
after treatment with lPEN 
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Structural Derivatives of Pentalinonsterol as Mechanistic Probes 
 With an established 
synthetic route to pentalinonsterol, 
structural derivatives of the 
compound were pursued for 
Structure Activity Relationship 
studies (SAR). The approach to 
analogue generation targeted the 
key ,-unsaturated ketone of the A-ring and the C17 side chain moiety. A-ring analogues were 
synthesized by Mr. Andrew Huntsman while my role involved the synthesis of the C17 side 
chain analogues.  
The first task required for derivatization of the C17 chain was to determine what 
electrophiles would be tolerated in the alkylation reaction. Figure 10 lists the different alkylating 
agents that were used in order to create new side chain analogues. The alkylation reaction was 
carried out using the procedure optimized for the preparation of pentalinonsterol, namely enolate 
generation with LiTMP followed by addition of the appropriate alkyl halide. After successful 
alkylation, the synthesis would be continued in the same manner employed for the preparation of 
pentalinonsterol. The key difference in the synthetic sequences was the re-evaluation of the 
solvent systems that needed to be used for flash column chromatography. Due to the extreme 
lipophilicty of these molecules, multiple solvent systems had to be tested and optimized for each 
alkylated and olefinated products.  The most difficult purifications were those of the alkylation 
products themselves due to the similar polarities between the mono and dialkylated products. In 
Figure 10 A list of the alkyating  agents used to make 
pentalinonsterol derivatives 
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order to achieve minimal coelution, the solvent polarity employed for flash column 
chromatography typically had to be reduced, resulting in much slower elution of the compounds.  
In order to understand why the alkylating agents were chosen it is important to compare 
their structures to that of dimethylallyl bromide. Reagent 1 is the saturated form of dimethylallyl 
bromide and closely resembles cholesterol. Reagent 2 was chosen to see if adding an aromatic 
substituent in place of the prenyl group would increase activity through potential π-π 
interactions. Reagent 3 was chosen in order to probe the importance of the C17 chain length. 
Reagents 4 and 5 allow us to probe the importance of the dimethyl portion of the prenyl group.  
As mentioned above, the electrophiles that could be tolerated in the alkylation reaction 
had to be probed. Only three of the alkylating agents seen in figure 10 were determined to be 
suitable electrophiles. Reagents 2, 3, and 4 alkylated successfully with yields of 55, 68, and 44% 
respectively. Most notably, only the most reactive alkylating agents were suitable for this 
reaction, possibly due to the relatively congested steric environment of the methyl ketone. It was 
surprising to see that reagent 5 was unable to be successfully alkylated to the sterol since it has 
similar reactivity to reagents 2, 4, and dimethylallyl bromide (other allylic or benzylic halides) 
which all alkylated successfully. The consideration of electrophile reactivity helps to explain 
why reagent 1 could not be successfully employed. Experiments are currently being performed to 
increase reagents 1’s electrophilicity by converting the bromine to a better leaving group.  A 
Finkelstein reaction was attempted on this material with NaI, however, only starting material was 
recovered. Other reactions can be employed such as triflation, although care must be taken not to 
introduce a leaving group that will subsequently eliminate. 
 Upon each successful alkylation reaction, new chromatographic solvent systems were 
required to successfully separate the products given that the lipophilicty was different. However, 
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once pure alkylated product was isolated the synthesis was continued in the same manner 
employed for the preparation of pentalinonsterol. Compounds RD36, RD50, and RD51 were 
successfully completed and submitted for biological testing. RD50 is unique because the 
olefination step was omitted in order to probe the importance of the side chains olefin. 
 
 Despite successful alkylation with benzyl bromide, isolation of the final analogue in this 
case was prevented by contamination issues. Triphenylphosphine was discovered in the 
1
H NMR 
and was found to be inseparable from the olefinated product. Trituration with hexanes was 
employed to remove the triphenylphosphine as seen in the NMR spectra in figures 11 and 12, 
however this derivative was soluble in hexanes so we could not purify this intermediate until the 
silyl ether deprotection. Another similar analogue was attempted where the olefination step was 
omitted, however this sample was contaminated with plasticizer. After multiple purification 
attempts with multiple solvent systems the impurities were still present in the sample as seen in 
figure 13. It is possible that these impurities could have been removed after the subsequent 
deprotection step, but due to multiple attempts at purification, the quantities of compound 
remaining were not sufficient to take forward in the synthesis. 
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Figure 11 Triphenylphosphine impurity after olefination 
 
Figure 12 Enhanced view of the PPh3 impurity 
 
 
PPh3 
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Figure 13 Display of the unknown impurities after the Oppenauer oxidation 
 
Compounds 4 and 5 were never completed due to poor reactivity of alkylating agents 1 
and 5. Since analogues were needed for biological testing the synthesis of these compounds was 
de-prioritized and temporarily put on hold.  The issue of sterol alkylation may be readdressed in 
future works.   
 
Unknown 
impurities 
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Figure 14 Structures of the analogues sent for biological testing 
 
 
Figure 15 Compounds tested in an MTT assay to determine the cytotoxicity against 
healthy dendritic cells 
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The Biological Activity of Pentalinonsterol Derivatives 
In order to probe the activity of each analogue it is important to compare the relative 
potency to PEN itself. Biological testing of the compounds highlighted in figure 14 were done in 
the Satoskar lab, and the results are displayed in figures 15-17.  
The first test that was performed on the analogues was an MTT assay. An MTT assay is a 
colorimetric assay that tests cell viability. In this assay the MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium) tetrazolium dye is added to each well in a well plate with healthy 
dendritic cells (DC’s). Each well is then dosed with a different concentration (25 or 50 μM) of 
the analogues and then after 24 hours the color of the wells is recorded as an optical density 
which correlates to the amount of living cells. The MTT is reduced enzymatically by 
oxidoreductase in the living cells to the insoluble formazan which has a purple color. This means 
that wells that have more purple color will have a higher optical density which corresponds to 
more cell proliferation.  
Figure 17 PEN analogues were tested to 
see their effects on IL-10 levels.  
Figure 16 PEN analogues were tested to see 
their effects on IL-12 levels 
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Analysis of the MTT assay data shows that all of the compounds are not toxic to the 
DC’s when compared to DMSO. It is important to note that DMSO itself is a relatively non-toxic 
compound that is frequently used as a carrier for in vitro and in vivo testing. DMSO is most 
commonly used as a solvent to dissolve hydrophobic drugs for this type of assay and is also used 
for cryopreservation of compounds. It has been employed in multiple different models
16
.   
 Analysis of figures 16 and 17 shows that all of the analogues that were tested were not as 
effective as PEN at increasing IL-12 levels but were equally or more effective at decreasing the 
IL-10 levels. Since IL-12 is responsible for IFN-γ production, it is optimal to show an increase in 
IL-12 levels
14. While none of the analogues were as effective as PEN, RD36 at 50 μM was the 
most effective at increasing these levels. Since IL-10 is responsible for inhibition of IL-12 it is 
ideal to see a decrease in IL-10 levels
17
. Compounds RD36 and RD51 seemed to be the most 
effective at inhibiting the production of IL 10.  
  
 
Figure 18 The reduction of colorless MTT to the purple Formazan in vivo. 
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Future Works 
 The Satoskar Lab is currently in the process of generating 
antileishmaial activity data for the submitted compounds. This 
data will be critical for further optimization of the compounds. 
This will also help to determine the role and function of the side 
chain. Currently it appears that RD36 seems to be the most 
promising compound with regard to adjuvant activity. It is possible that adjuvant and 
antileishmanial activity could be optimized in these compounds concurrently or separately 
depending on the potential application. 
In order to complete the analogue series we will ultimately want to go back and finish the 
synthesis of the molecules that are shown in figure 19. These compounds will allow us to fully 
understand the importance of the prenyl side chain that is found on PEN. The synthesis of 
compound 2 can be accomplished utilizing the procedure that was developed. In this case, 
however, more care will have to be taken in order to prevent the introduction or production of 
impurities in the synthesis. We believe that the alkylation issues that we have encountered in the 
synthesis of compound 5 can be overcome since the alkylation reagent has similar reactivity to 
other reagents that have been employed successfully. We may need to use HMPA in 
combination with the LiTMP In order to make a more “naked” and reactive enolate. Switching  
the solvent to a more polar aprotic solvent may increase reactivity through stabilization of the 
Figure 19 Remaining compounds to be synthesized to complete the analogue library 
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intermediate of the SN2 reaction however solubility issues may arise if the solvent becomes too 
polar. It was mentioned earlier that compound 4 might be able to be made if we can modify the 
leaving group. Introduction of a triflate group on the electrophile will increase its reactivity, 
although we must be careful because as better leaving groups are introduced the risk of 
elimination before the molecule reacts increases.  
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Part II: The Total Synthesis of Scytonemide A, a Novel 20S Proteasome Inhibitor 
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Chapter 1: The Ubiquitin Proteasome Pathway and Its Inhibitors 
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The Ubiquitin Proteasome Pathway 
 The ubiquitin proteasome pathway (UPP) is responsible for the degradation of 
intracellular proteins. The system is capable of degrading proteins from the nucleus, cytosol, 
membrane anchored, and secretory pathway-compartmentalized proteins
18
. Due to the vast array 
of cellular targets that this pathway can affect, the UPP is responsible for regulation of cell cycle 
and division, neuronal works, ion channels, DNA repair, regulation of immune and inflammatory 
response, development and differentiation, and apoptosis
18
. Due to the multifaceted purpose of 
the UPP its regulation is critical to cell vitality and viability.  
 Degradation of cellular proteins can be broken down into two successive steps which are 
displayed in figure 20. The first step involves the covalent polyubiquitination of single ubiquitin 
units to the protein that is to be degraded. The ubiquitination process is driven by three key 
enzymes. Ubiquitin activating enzyme (E1) activates the C-terminal glycine of a single ubiquitin 
molecule which becomes coordinated to an ubiquitin-protein ligase enzyme (E3) by the ubiquitin 
conjugating enzyme (E2). E3 is the enzyme that covalently links ubiquitin to a lysine residue of 
the protein. Once the protein is polyubiquitinated, through subsequent ubiquitination of lysine 
residues of the previous ubiquitin molecule, it becomes recognized by the proteasome. 
 The 26S proteasome is responsible for the degradation of polyubiquitinated proteins and 
it can be broken down into two subunits: The 20S proteasome, which is responsible for the 
catalytic degradation of proteins, and the two flanking 19S subunits which recognize the 
polyubiquitinated proteins.  It is currently theorized that entry of the protein into the catalytic 
20S core does not take place until the 19S subunit undergoes a conformational change which 
opens up a pore. Once the protein enters the 20S proteasome it is degraded by trypsin, 
chymotrypsin, or post-glutamyl peptidase sites.  
38 
 
 
 
Figure 20 The Ubiquitin Proteasome Pathway
18
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UPP Inhibitors 
 Due to the UPP’s involvement in the degradation of over 80% of cellular proteins19 it can 
be understood why defects in this pathway can have dire consequences on cellular health. The 
first proteasome inhibitors were developed as mechanistic probes in order to understand the 
function of the 20S proteasome. Initial inhibitors lacked specificity, potency, or availability
19
; 
however significant improvements have been made. Recent biological studies have demonstrated 
that proteasome inhibitors are more cytotoxic towards malignant cells than healthy cells, 
although the exact reason for this is still undetermined. It is believed that the highly proliferative 
tumor cells have increased protein synthesis rates and inhibiting the proteolysis of key proteins 
can lead to apoptosis. It is well understood that the cellular cycle is tightly controlled through 
cyclins and cyclin dependent kinases (CPK’s) and loss of control of this system can lead to 
oncogenesis
19
. The UPP is responsible for the degradation of many of the proteins that are 
critical for cellular regulation. If proteasome inhibitors successfully inhibit the proteolysis of 
cyclins or specific regulatory proteins then the cell undergoes induced cell death via cell cycle 
arrest
19
. The UPP is also responsible for the degradation of intracellular pro and anti-apoptotic 
proteins. Inhibition of the proteasome results in the upregulation of proapoptotic factors while 
reducing the levels of antiapoptotic factors. This results in apoptosis in cancer cells that have 
disregulated levels of these factors. It has been proven that the proteasome inhibitors can be used 
as an effective single component treatment or they can be used in conjunction with other 
chemotherapeutics to increase their efficacy
19
. Three major classes of proteasome inhibitors have 
or are currently being developed for clinical use. There are peptide boronic acids, peptide 
epoxyketones, and β-lactones which bind either reversibly or irreversibly to the catalytic site of 
the 20S proteasome.  
40 
 
Bortezomib 
Bortezomib is a reversible 20S proteasome inhibitor. This drug appeared to be most 
effective against multiple myeloma and was first approved by the FDA as a third-line treatment 
in 2003. The drug became a first-line treatment in 2008 for multiple myeloma. It is mainly used 
in tandem with other chemotherapeutic agents in order to overcome resistance and sensitivity 
issues. A major setback with Bortezomib is its inability to effectively treat solid tumors. The 
drug showed promise in preclinical studies but failed to perform in clinical trials. This limitation 
has opened the door for broader spectrum proteasome inhibitors
19
.  
Carfilzomib 
Carfilzomib is a member of the epoxyketone family of proteasome inhibitors and binds to 
the catalytic site of the 20S proteasome at two different sites. The drug binds irreversibly to both 
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the amino and hydroxyl groups of the catalytic Threonine residue. Carfilzomib is shown to have 
similar potency to Bortezomib however this drug is more selective. This drug is also used with 
other chemotherapeutics for a synergistic effect
19
. Carfilzomib received FDA approval in July 
2012 for the treatment of multiple myeloma in patients who have previously received other 
therapies, including Bortezomib. 
Salinosporamide A 
 Salinosporamide A is a β-lactone proteasome inhibitor that is capable of binding to all 3 
catalytic sites within the 20S proteasome. Another benefit of this drug over Bortezomib and 
Carfilzomib is its ability to be administered orally. This drug is also effective against Bortezomib 
resistant multiple myeloma cells lines
19
. 
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MLN9708, CEP-18770, andONX0912 
The remaining three proteasome inhibitors seen above are in the beginning of their 
clinical trials. CEP-18770 and MLN9708 are Bortezomib derivatives. MLN9708 has a 
significantly shorter half-life than Bortezomib which may increase its tissue distribution. It is 
also important to note that this compound is a prodrug that gets hydrolyzed to its biologically 
active form, MLN2238, in vivo. CEP-18770 shows improved cytotoxicity towards multiple 
myeloma cells while being less cytotoxic towards healthy cells. Compound ONX 0912 is an 
orally bioavailable version of Carfilzomib and is therefore more clinically desirable. All three of 
these compounds are in phase I or II of clinical trials
19
. 
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Chapter 2: The Discovery and Approach Towards the Total Synthesis of Scytonemide A 
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The Discovery and Isolation of Scytonemide A 
Natural products and their derivatives are responsible for 79.8% of all of the new 
anticancer drugs since 1981
9
. This number has actually risen over the past 10 years despite 
advances in combinatorial chemistry and high throughput screening. In order to discover new 
natural products with high proteasome inhibitory potency, researchers are looking towards 
natural sources such as plants and microorganisms. It is important to continue researching and 
discovering new proteasome inhibitors because there are only two FDA approved drugs and both 
of these have deleterious side effects or lack activity against certain types of tumors. With this in 
mind, cyanobacteria have been found to be an excellent source of multiple classes of secondary 
metabolites that have activity against many different diseases. As part of a collaborative research 
program project grant (P01) through the NIH, the Orjala lab at The University of Illinois Chicago 
employed bioassay-guided fractionation techniques on lyophilized Scytonema hofmannii in order 
to discover new novel 20S proteasomes inhibitors.  
 
 
Figure 21 Scytonemide A 
 
Scytonemide A 
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Scytonemide A, seen in figure 21, was reported to be a novel 20S proteasome inhibitor in 
the Orjala lab in 2010
20
. Two related compounds, Scytonemides A and B, were isolated from the 
100% MeOH fraction, although only Scytonemide A showed potent inhibition of the 20S 
proteasome with an IC50 of 96 nM. While Scytonemide A showed promising in vitro proteasome 
activity (Table 1), it lacked activity in an HT-29 cell based assay. This was surprising because 
these cells have been shown to be sensitive towards proteasome inhibitors
20
. A luminescence 
based assay was used to ascertain the reason for the drastic decrease in activity and found that 
the poor result was due to the poor chemical or metabolomic stability of Scytonemide A. 
Scytonemide A showed activity at 6.7 µM in the luminescence based assay whereas it showed no 
activity at all in the HT-29 assay. 
Compound    Scytonemide A 
IC50 (20S Proteasome, chymotrypsic catalytic activity)          96 nM 
ED50 (HT-29 cytotoxic assay)       >20 µg/ml 
ED50 (luminescence based assay)                    6.7 µM 
 
Proposed Mechanism of Action 
 Scytonemide A contains a unique imine linkage which is highlighted in red in figure 21. 
This functionality is relatively unique for a cyclic peptide and is proposed to be responsible for 
its mode of inhibition. To understand why Scytonemide A acts as a 20S proteasome inhibitor it is 
important to understand how the clinically approved proteasome inhibitors work. The schemes 
below display the mechanisms of action for the 3 different classes of the clinically used 
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proteasome inhibitors as well as another proteasome inhibitor, fellutamide B, which has been 
shown to increase Nerve Growth Factor in cells
21
. 
  
 
β-lactone inhibitor Mechanism (Salinosporamide A) 
 
 
Boronic Acid Inhibitor Mechanism (Bortezomib) 
Epoxyketone Inhibitor Mechanism (Carfilzomib) 
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The schemes shown above all demonstrate the mechanism of action for the corresponding 
drugs. The common theme for every drug is the formation of a covalent bond between the 
secondary hydroxy of the Threonine residue with an electrophilic group whether it is a carbonyl 
or a boronic acid moiety. The boronic acid and peptidyl aldehyde inhibitors form a reversible 
covalent linkage through formation of a hemiacetal-like intermediate which can be hydrolyzed 
back to the corresponding free acid and 2° hydroxyl of the Threonine.  Both the β-lactone and 
epoxyketone inhibitors form irreversible covalent linkages with the Threonine residue within the 
20S proteasome. In the case of the salinosporamide A the Threonine residue gets deprotonated 
which then opens the lactone through nucleophilic attack of the carbonyl. The resulting free 
alcohol then becomes deprotonated and subsequently displaces the primary chlorine through an 
SN2 reaction to create a tetrahydrofuran. This furan can then H-bond to the primary amine of the 
Threonine residue creating a very stable intermediate that is irreversibly bound. In the case of the 
Peptidyl Aldehyde Inhibitor Mechanism (fellutamide B) 
 
Figure 22 Proposed hydrolysis of the imine to the corresponding peptidyl aldehyde 
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epoxyketone inhibitor the deprotonated Threonine hydroxyl attacks the α-ketone to the Leucine 
residue. The primary amine then becomes deprotonated which then allows epoxide opening with 
the nucleophilic amine to occur to form a morpholine ring. Since Scytonemide A contains the 
unique imine linkage we propose that its mechanism of action is most similar to peptidyl 
aldehyde inhibitor fellutamide B. One possible mechanism for its proteasome activity involves 
the hydrolysis of the imine to the corresponding peptidyl aldehyde and the free amine, seen in 
figure 22, which can then go through the same type of mechanism reported for fellutamide B. 
An alternative proposed mechanism is the direct addition of the Threonine residue in the 
chymotrypsin subunit to the protonated imine. The imine would be predicted to have similar 
reactivity to an aldehyde which leads us to believe you could get direct formation of the 
hemiaminal seen in figure 23. It is important to note that both of these mechanisms would 
proceed through a reversible process.  
 In order to elucidate the actual mechanism of action as well as perform more biological 
studies it is paramount that more scytonemide A is synthesized. The isolation process was only 
able to isolate 1.2 mg of pure scytonemide A from 8 liters of cell culture
20
. In order to obtain 
more scytonemide A, a synthetic scheme had to be developed that would allow quick and facile 
production of the natural product as well as allow quick and easy modification to create 
structural analogues and mechanistic probes.  
 
 
 
 
 
                
Figure 23  Hemiaminal formation resulting in reversible inhibition of the 20S 
proteasome 
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The Total Synthesis of Scytonemide A 
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In order to synthesize scytonemide A we first had to perform a retrosynthesis, seen in 
scheme 2 above, that we could employ for the forward synthesis of this novel secondary 
metabolite. We envisioned that the imine linkage could be formed from a C terminal peptidyl 
aldehyde on a Leucine residue with an N terminal primary amine on the tyrosine residue. 
Mahariel et al. has reported the in situ macrocylization of nostocyclopeptide through the 
formation of an imine linkage of a peptidyl aldehyde at the C terminus with a primary amine at 
the N terminus
22
. The synthesis of the polypeptide would be done in situ via a solid phase protein 
synthesis (SPPS) of fluorenylmethyloxycarbonyl (Fmoc) protected amino acids. The first residue 
that would be used in the SPPS would be a valine residue that is covalently bound to a 
polystyrene Wang resin at the C terminus leaving an Fmoc protected N terminus. Subsequent 
deprotection of the Fmoc under basic conditions would afford a primary amine that could 
undergo subsequent coupling with the next Fmoc protected amino acid in sequence. The Wang 
resin is acid labile which means that we wanted to employ acid labile protecting groups on the 
 
Scheme 2 The retrosynthesis of scytonemide A 
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chemically reactive side chains of the Serine, Glutamine, and Tyrosine residues. Once the six 
residue polypeptide is created, the side chains of the molecule could be globally deprotected and 
the valine residue cleaved from the solid support. In order to create the necessary peptidyl 
aldehyde derivative of Leucine, seen in the bottom left of scheme 2, the amino acid would be 
synthetically modified prior to coupling with the polypeptide. In order to achieve this, the 
aldehyde of the Leucine would be protected as an acetal in order to prevent polymerization of the 
peptidyl aldehyde and the free amine of the final product after deprotection of the Cbz protecting 
group on the amine. Oxidation of the primary alcohol to the aldehyde was envisioned to be 
accomplished via a Swern oxidation of L-Leucinol which would be derived from an LAH 
reduction of Leucine followed by a Cbz protection of the primary amine.  
The Forward Synthesis of the Leu/Ala Peptidyl Aldehyde 
 The forward synthesis starts with pure L-Leucine which undergoes an LAH reduction to 
generate the primary alcohol. The reaction went to completion according to TLC and purification 
of the crude product was difficult due to the high polarity of the product. Initially it appeared that 
the Cbz protection of the free amine was unsuccessful, although it was later determined that the 
product of the LAH reduction was very unstable and the crude material had to be carried forward 
immediately after workup. The resulting carbamate product was stable and easily purified via 
 
Scheme 3 The optimized forward synthesis of the modified leu/ala residue 
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flash column chromatography. According to the synthetic plan, this material was subjected to 
Swern oxidation conditions to affect the oxidation of the primary alcohol to the corresponding 
aldehyde. Multiple attempts were made to carry out this conversion, however, they only afforded 
starting material. Based on these results we decided to switch to stronger oxidizing agents such 
as Dess-Martin Periodane and IBX, although neither of these oxidants proved to be successful 
either. Successful oxidation to the aldehyde was finally achieved upon treatment of the primary 
alcohol with PDC. The acetal protected aldehyde was then generated after being treated with 
ethylene glycol and catalytic p-toluenesulfonic acid in toluene. A Dean-Stark apparatus was used 
to remove the water formed during formation of the acetal and to drive the reaction to 
completion. Removal of the Cbz protecting group is to be done with H2, Pd/C in EtOAc to afford 
the final product, but this has not been carried out to date.  
 This same synthetic scheme has been used on L-Alanine to facilitate the Alanine scan 
that we envision performing. Alanine and Leucine both contain a lipophilic side chain that is 
chemically inert which is why we were able to utilize the same scheme on a different amino acid.  
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The Solid Phase Protein Synthesis of Scytonemide A 
 SPPS will be utilized to construct the first six residues of scytonemide A. This has not yet 
been accomplished. We have optimized the conditions, however, that are going to be used in 
order to generate the polypeptide. The resin beads containing the valine residue could be 
sufficiently swelled in DMF for 3 hours prior to coupling. After rinsing the beads three times 
with DMF, a 20% solution of piperidine in DMF was added and the mixture was allowed to stir 
on an orbital shaker for 2.5 hours. This solution was washed from the beads by 3 additions of 
DMF and then then the coupling reagents, HOAt and DIPEA in DMF, were added to the beads. 
This mixture remained on the orbital shaker for 3 hours before being washed three times with 
DMF. After washing and filtering of the beads, a solution of 95% TFA: 2.5% TES: and 2.5% 
H2O was added which acted as the decoupling and deprotection solution. This mixture was 
allowed to stir for 2.5 hours and then the product was removed from the beads by filtration 
through a Buchner funnel. The solution was then pumped down via vacuum filtration and the 
organics were extracted with diethyl ether. The decoupled product seen in scheme 4 was soluble 
in the organic layer. Although this was somewhat surprising, the Fmoc group is likely 
 
Scheme 4 Optimized conditions for the SPPS 
 
(1) Deprotection with 20% piperidine in 
DMF (2) Coupling with HOAt and DIPEA 
in DMF (3) Decoupling with 95% TFA: 
2.5%TES: 2.5% H2O 
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responsible for making the molecule lipophilic enough to be extracted into the organic layer as 
opposed to the aqueous layer. After the final Fmoc deprotection (prior to decoupling and 
deprotection) the polypeptide will most likely stay in the aqueous layer and all of the organics 
will be extracted into the organic layer.  
Future Works 
 The most important goal that we have yet to achieve is the total synthesis of scytonemide 
A. Once the linear polypeptide is created and cleaved from the Wang resin, we want to attach the 
peptidyl aldehyde residue to the C terminus of the valine. After this step we merely have to 
deprotect the Fmoc group on the N terminus tyrosine and the acetal on the C terminus.  
 Once the total synthesis has been completed we want to utilize the procedures that we 
have already created to perform an Alanine scan on all of the amino acids, including the peptidyl 
aldehyde of Leucine, contained in scytonemide A. This will help us probe the biological 
significance of each amino acid in the protein because Alanine is a chemically inert, non-bulky, 
methyl functional group that contains the same stereochemistry as most of the AA’s.  
 
 
Figure 24 The Alanine Scan of Scytonemide A 
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 The last goal for our future work on this project is to determine the mechanism of action 
of scytonemide A through structural modification of the natural product. In order to determine if 
the linear peptidyl aldehyde is responsible for the inhibition we want to prevent the cyclization of 
scytonemide A. In order to do this we have to methylate the N terminal amine prior attachment 
of the peptidyl aldehyde residue which will prevent imine formation upon coupling and 
deprotection of the acetal. 
 
  
 
Scheme 5 The Linear derivative of scytonemide A 
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Part III: Experimentals 
TBS protection of the C3 alcohol pregnenolone 
 
A solution of Pregnenolone, 2, (3.000 g, 9.749 mmol), tert-butyldimethylsilyl chloride (2.143 g, 
14.21 mmol), and imidazole (0.807 g, 11.85 mmol) in DMF (158 mL) was reacted at 21 °C 
overnight.  The reaction mixture was quenched with cold deionized water.  The resulting white 
precipitation, 3, was collected via vacuum filtration and washed with cold deionized water (3X10 
mL) to obtain pure silylated product (3.896 g, 9.045 mmol, 95%) as a white powder: mp 163 °C; 
1H NMR (CDCl3, 400 MHz) δ 5.31 (m, 1H), 3.48 (m, 1H), 2.53 (t, 1H), 2.12 (s, 3H), 0.99 (s, 
3H), 0.88 (s, 9H), 0.62 (s, 3H), 0.05 (s, 6H); 13C NMR (CDCl3, 100 MHz) δ 209.5, 141.5, 
120.8, 72.5, 63.7, 56.9, 50.0, 43.9, 42.7, 38.8, 37.3, 36.5, 32.0, 31.8, 31.7, 31.5, 25.9, 24.4, 22.7, 
21.0, 19.4, 18.2, 13.2, -4.6; IR (film): 1701 cm−1; HRMS-TOF m/z (M + Na)+ calcd for 
C27H46O2Si 453.3165, found 453.3165.  
 
General procedure for the alkylation: 
 
To a solution of tetramethylpiperidine (0.357 mL, 2.114 mmol) in THF (14.1 mL) at -78 °C was 
added n-butyl lithium (2.5 M in hexanes, 0.790 mL, 1.973 mmol).  The resulting solution was 
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allowed to stir for 35 minutes at -78 °C before the addition of a solution of 3 (0.6072 g, 1.410 
mmol) in THF (5.7 µL).  After 3 h of stirring at -78 °C, the alkylating agent (0.1755 mL, 2.819 
mmol) was added drop wise to the reaction mixture, warmed to 21 °C, and stirred overnight.   
The reaction was quenched with excess aqueous ammonium chloride.  The separated and 
aqueous layer was extracted with ethyl acetate.  The combined organic layers were then dried 
with anhydrous sodium sulfate and concentrated under reduced pressure.  The crude product was 
purified by silica gel column chromatography (EtOAc:DCM:hexanes, 1:1:98) to afford pure 
mono-alkylated product as a white solid. 
 
Monoalkylated sterol. (0.397 g, 68%) The general alkylation procedure was utilized with 
dimethylallyl bromide as the alkylating reagent to generate compound 4 as a white solid  mp 
120-121 °C; 1H NMR (CDCl3, 400 MHz) δ 5.31 (d, 1H), 5.06 (t, 1H), 3.48 (m, 1H), 2.50 (t, 
1H), 2.39 (m, 2H), 2.21 (m, 5H), 2.00 (m, 2H), 1.81 (m, 1H), 1.66 (s, 3H), 1.61 (s, 3H), 1.48 (m, 
3H), 0.99 (s, 3H), 0.88 (s, 9H), 0.60 (s, 3H), 0.05 (s, 6H); 13C NMR (CDCl3, 100 MHz) δ 211.6, 
141.9, 132.8, 123.6, 121.3, 72.9, 63.3, 57.4, 50.5, 44.7, 44.6, 43.2, 39.4, 37.8, 37.0, 32.5, 32.3, 
32.2, 26.3, 26.1, 24.9, 23.3, 22.8, 21.5, 19.8, 18.6, 18.0, 13.8, -4.1; IR (film): 1704 cm−1; 
HRMS-TOF m/z (M + Na)+ calcd for C32H54O2Si 521.3791, found 521.3814. 
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Monoalkylated sterol. (0.380 g, 60%) The general alkylation procedure was utilized with 
iodomethane as the alkylating reagent to generate compound 8 as a white solid: 
1
H NMR (400 
MHz, CDCl3) δ 5.72 (s, 1H), 4.87 (d, J = 1.3 Hz, 1H), 4.77 (s, 1H), 1.17 (s, 3H), 1.01 (t, J = 7.4 
Hz, 3H), 0.60 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 199.53, 171.47, 150.87, 123.80, 108.48, 
56.12, 55.78, 53.97, 43.08, 38.64, 38.51, 36.03, 35.72, 33.98, 32.91, 31.97, 30.29, 25.81, 24.11, 
21.10, 17.40, 12.83. 
 
Monoalkylated sterol. (0.256 g, 44%) The general alkylation procedure was utilized with allyl 
bromide as the alkylating reagent to generate compound 9 as a white solid: mp: 
1
H NMR (300 
MHz, CDCl3) δ 5.82 (ddt, J = 16.6, 10.2, 6.4 Hz, 2H), 5.33 (d, J = 5.0 Hz, 2H), 5.09 – 4.94 (m, 
4H), 3.56 – 3.44 (m, 2H), 2.47 (d, J = 7.1 Hz, 3H), 1.01 (s, 6H), 0.90 (s, 17H), 0.63 (s, 5H), 0.08 
(d, J = 4.0 Hz, 12H); 
13
C NMR (101 MHz, CDCl3) δ 211.03, 141.93, 137.95, 121.28, 115.48, 
72.94, 63.38, 57.41, 50.47, 44.65, 43.82, 43.17, 39.36, 37.78, 37.00, 32.44, 32.26, 32.23, 30.12, 
28.17, 26.34, 24.94, 23.34, 21.47, 19.83, 18.67, 13.80, -4.18. 
 
General procedure for the wittig olefination: 
 
To a solution of methyltriphenylphosphonium bromide (3.940 g, 11.02 mmol) in THF (5.5 mL) 
at 0 °C was added n-butyl lithium (2.5 M in hexanes, 4.19 mL, 10.47 mmol).  The resulting 
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reaction mixture was stirred at 0 °C for 1 hour before adding a solution of the alkylated product 
(0.550 g, 1.102 mmol) in THF (5.5 mL).  The reaction was brought to reflux and stirred 
overnight before being quenched with deionized water.  The organic layer was removed and the 
aqueous layer was extracted three times with ethyl acetate.  Combined organic layers were dried 
over anhydrous sodium sulfate and concentrated under reduced pressure.   Crude product was 
then purified via silica gel column chromatography (DCM:EtOAc:hexanes, 1:1:98) to obtain the 
olefinated compound as a pure solid.  
 
Olefinated product.  (0.489 g, 0.984 mmol, 89%) The general olefination procedure utilized 
compound 4 to generate compound 5 as a white solid as a white solid:   mp 86 °C; 1H NMR 
(CDCl3, 400 MHz) δ 5.31 (d, J = 5.1 Hz, 1H), 5.10 (m, 1H), 4.87 (s, 1H), 4.78 (s, 1H), 3.48 (m, 
1H), 2.26 (m, 1H), 2.07 (m, 7H), 1.79 (m, 3H), 1.68 (s, 3H), 1.61 (s, 3H), 1.51 (s, 10H), 1.18 (m, 
3H), 0.99 (s, 3H), 0.88 (s, 9H), 0.57 (s, 3H), 0.05 (s, 6H); 13C NMR (CDCl3, 400 MHz) δ 149.3, 
141.5, 131.4, 124.3, 121.0, 72.5, 71.8, 56.6, 55.9, 50.3, 43.0, 42.7, 38.7, 37.3, 36.6, 32.2, 31.8, 
27.1, 25.9, 25.8, 25.7, 21.1, 19.4, 18.2, 17.7, 12.7, 13.3, -4.5; IR (film): 2928 cm−1.  
 
Olefinated product (0.3162 g, 86%) The general olefination procedure utilized compound 8 to 
generate compound 10 as a white solid as a white solid: 
1
H NMR (300 MHz, CDCl3) δ 5.33 (d, J 
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= 4.6 Hz, 1H), 4.87 (s, 1H), 4.78 (s, 1H), 3.56 – 3.43 (m, 1H), 1.04 (d, J = 7.4 Hz, 3H), 1.01 (s, 
4H), 0.90 (s, 10H), 0.58 (s, 3H), 0.07 (s, 6H). 
 
Olefinated product (0.0417 g, 43%) The general olefination procedure utilized compound 9 to 
generate compound 11 as a white solid as a white solid: 
1
H NMR (300 MHz, CDCl3) δ 5.91 – 
5.75 (m, 1H), 5.32 (d, J = 5.2 Hz, 1H), 5.07 – 4.91 (m, 2H), 4.88 (s, 1H), 4.81 (s, 1H), 3.57 – 
3.34 (m, 1H), 1.01 (s, 3H), 0.91 – 0.88 (m, 9H), 0.59 (s, 3H), 0.08 – 0.05 (m, 6H); 13C NMR 
(101 MHz, CDCl3) δ 149.16, 141.19, 139.14, 122.02, 114.78, 110.09, 72.17, 57.06, 56.38, 50.66, 
43.50, 42.69, 39.09, 37.66, 37.39, 36.96, 33.10, 32.69, 32.22, 32.04, 30.12, 26.24, 24.61, 21.54, 
19.84, 13.17. 
 
 
General procedure for the TBAF deprotection: 
 
A solution of A (0.124 g, 0.250 mmol) and tetrabutylammonium fluoride (1.0 M in THF, 0.5 
mL, 0.5 mmol) in THF (1.25 mL) was stirred at 21 °C overnight.  The reaction mixture was 
concentrated under reduced pressure and the resulting residue was purified by silica gel column 
chromatography (EtOAc-hexanes, 3:17) to give the deprotected product. 
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Deprotected product (0.094 g, 94%) The general TBAF deprotection procedure was utilized 
with compound 5 as the starting material to produce compound 6 as a white solid: mp 89-91 °C; 
1H NMR (CDCl3, 400 MHz) δ 5.35 (d, J = 5.0 Hz, 1H), 5.11 (m, 1H), 4.87 (s, 1H), 4.78 (s, 1H), 
3.52 (m, 1H), 2.27 (m, 2H), 2.05 (m, 6H), 1.82 (m, 4H), 1.68 (s, 3H), 1.60 (s, 3H), 1.49 (s, 7H), 
1.11 (m, 6H), 1.00 (s, 3H), 0.57 (s, 3H); 13C NMR (CDCl3, 400 MHz) δ 149.2, 140.7, 131.4, 
124.3, 121.6, 109.3, 71.8, 71.7, 56.6, 55.9, 50.2, 43.0, 42.2, 38.6, 37.6, 37.2, 36.5, 32.2, 31.8, 
31.6, 27.1, 25.8, 25.7, 24.2, 21.1, 19.4, 17.7, 12.7; HRMS-TOF m/z (M + Na)+ calcd for 
C27H42O 405.3133, found 405.3151. 
 
Deprotected product (0.217 g, 93%) The general TBAF deprotection procedure utilized 
compound 10 to produce compound 12 as a white solid: 
1
H NMR (300 MHz, CDCl3) δ 5.36 (d, J 
= 5.2 Hz, 1H), 4.86 (s, 1H), 4.77 (s, 1H), 3.53 (ddd, J = 15.4, 10.9, 4.5 Hz, 1H), 1.02 (dd, J = 9.2, 
5.5 Hz, 7H), 0.57 (s, 3H). 
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Deprotected product (0.0207g, 66%) The general TBAF deprotection procedure utilized 
compound 11 to produce compound 13 as a white solid: 
1
H NMR (300 MHz, CDCl3) δ 5.81 (ddt, 
J = 16.7, 10.1, 6.4 Hz, 2H), 5.34 (d, J = 5.3 Hz, 2H), 5.08 – 4.92 (m, 4H), 3.52 (ddd, J = 15.5, 
11.0, 4.5 Hz, 2H), 1.25 (s, 5H), 1.00 (s, 6H), 0.62 (s, 5H). 
 
Deprotected product (0.218g, 50%) The general TBAF deprotection procedure utilized 
compound 9 to produce compound 14 as a white solid: 
1
H NMR (300 MHz, CDCl3) δ 5.90 – 
5.70 (m, 2H), 5.34 (d, J = 5.3 Hz, 2H), 5.10 – 4.91 (m, 4H), 3.52 (ddd, J = 15.5, 11.0, 4.5 Hz, 
2H), 1.24 (d, J = 6.4 Hz, 5H), 1.00 (s, 6H), 0.62 (s, 5H). 
 
General procedure for the oppenaeur oxidation 
 
To a solution of A (0.434 g, 1.135 mmol) and cyclohexanone (1.175 mL, 11.35 mmol) in toluene 
(22.7 mL) at reflux was added aluminum isopropoxide (0.116 g, 0.568 mmol).  The reaction was 
stirred at reflux overnight.  The reaction mixture was concentrated under reduced pressure, taken 
up in deionized water, and extracted three times with ethyl acetate.  Crude product was purified 
by silica gel column chromatography (EtOAc:hexanes, 1:19) to afford the completed analogue. 
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Oppenaeur product (0.386 g, 89%) The general oppenaeur procedure was utilized to afford 1 
(pentalinonsterol) as a white solid: mp 89-91 °C; 1H NMR (CDCl3, 400 MHz) δ 5.35 (d, J = 5.0 
Hz, 1H), 5.11 (m, 1H), 4.87 (s, 1H), 4.78 (s, 1H), 3.52 (m, 1H), 2.27 (m, 2H), 2.05 (m, 6H), 1.82 
(m, 4H), 1.68 (s, 3H), 1.60 (s, 3H), 1.49 (s, 7H), 1.11 (m, 6H), 1.00 (s, 3H), 0.57 (s, 3H); 13C 
NMR (CDCl3, 400 MHz) δ 149.2, 140.7, 131.4, 124.3, 121.6, 109.3, 71.8, 71.7, 56.6, 55.9, 50.2, 
43.0, 42.2, 38.6, 37.6, 37.2, 36.5, 32.2, 31.8, 31.6, 27.1, 25.8, 25.7, 24.2, 21.1, 19.4, 17.7, 12.7; 
HRMS-TOF m/z (M + Na)+ calcd for C27H42O 405.3133, found 405.3151. 
 
Oppenaeur product (0.150 g, 69%) The general oppenaeur procedure was utilized to afford x as 
a white solid: 
 
Oppenaeur product (6.89 mg, 33%) The general oppenaeur procedure was utilized to afford x 
as a white solid: 
1
H NMR (300 MHz, CDCl3) δ 5.88 – 5.75 (m, 1H), 5.73 (s, 1H), 5.07 – 4.93 (m, 
2H), 1.18 (s, 3H), 0.66 (s, 3H). 
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Oppenaeur product (4.12 mg, 19%) The general oppenaeur procedure was utilized to afford x 
as a white solid: 
1
H NMR (300 MHz, CDCl3) δ 5.81 (ddd, J = 16.6, 10.3, 6.2 Hz, 1H), 5.73 (s, 
1H), 4.98 (dd, J = 19.3, 13.9 Hz, 2H), 4.90 (s, 1H), 4.81 (s, 1H), 1.18 (s, 3H), 0.62 (s, 3H). 
General procedure for the LAH reduction 
 
To a 0 °C solution of THF (9.5 mL) was added LAH portion wise (0.3727 g, 9.822 mmol) 
followed by the addition of the L-amino acid (0.250 g, 2.806 mmol). This reaction was refluxed 
overnight and then quenched via the Fieser method. The product was extracted three times with 
EtOAc, and concentrated in vacuo. The crude oil was checked by 
1
H NMR and then immediately 
carried forward into the next reaction without further purification.  
 
Reduced product (crude 0.320 g) The general procedure for the LAH reduction was utilized to 
afford the product, 15, as a yellow oil from the starting material, L-Alanine. 
1
H NMR (300 MHz, 
CDCl3) δ 3.54 (ddd, J = 10.5, 4.0, 0.4 Hz, 1H), 3.23 (dd, J = 10.5, 7.8 Hz, 1H), 3.01 (dqd, J = 
12.9, 6.4, 4.0 Hz, 1H), 1.05 (dd, J = 6.4, 0.5 Hz, 3H). 
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Reduced product (crude 0.4817 g) The general procedure for the LAH reduction was utilized to 
afford the product, 20, as a yellow oil from the starting material, L-Leucine. 
1
H NMR (400 MHz, 
CDCl3) δ 3.42 – 3.34 (m, 1H), 3.07 (dd, J = 10.5, 8.1 Hz, 1H), 2.74 (dt, J = 14.5, 5.3 Hz, 1H), 
1.61 – 1.45 (m, 1H), 1.02 (t, J = 7.0 Hz, 2H), 0.75 (dd, J = 10.9, 6.6 Hz, 6H). 
General procedure for the Cbz protection 
 
Benzyl chloroformate (0.821 mL, 5.753 mmol) was added slowly to a precooled (0 °C) solution 
of the reduced amino acid (0.482 g, 4.110 mmol) and triethylamine (0.858 mL, 6.165 mmol) in 
chloroform (20.5 mL).  The reaction was allowed to stir overnight and warm to room 
temperature before it was evaporated under reduced pressure. Ethyl acetate was added to the 
resulting oil and then the solution was washed with 1M NaOH, brine, and dried with MgSO4. 
The resulting residue was purified via flash column chromatography (EtOAc: Hexanes, 2:3) 
 
Cbz protected product (0.6439 g, 3.077 mmol) The general Cbz protection procedure utilized 
compound 15 to afford the product, 16, as a white sold. 
1
H NMR (300 MHz, CDCl3) δ 7.37 – 
7.29 (m, 6H), 5.09 (s, 2H), 3.89 – 3.77 (m, 1H), 3.64 (dd, J = 11.0, 3.9 Hz, 1H), 3.51 (dd, J = 
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11.0, 5.9 Hz, 1H), 1.16 (d, J = 6.8 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 156.68, 136.42, 
128.59, 128.21, 128.17, 66.85, 66.60, 48.97, 17.28. 
 
Cbz protected product (0.356 g, 1.416 mmol) The general Cbz protection procedure utilized 
compound 20 to afford the product, 21, as a white sold. 
1
H NMR (400 MHz, CDCl3) δ 7.37 – 
7.27 (m, 10H), 5.08 (s, 4H), 3.78 (d, J = 3.4 Hz, 2H), 3.65 (d, J = 10.2 Hz, 2H), 3.51 (s, 2H), 
1.70 – 1.58 (m, 2H), 1.38 – 1.25 (m, 4H), 0.92 (d, J = 6.4 Hz, 11H). 
General procedure for PDC oxidation 
 
To a solution of Cbz protected amino acid (80.6 mg, 0.3852 mmol) in DCM and cooled to 0 °C 
was added pyridinium dichromate (0.432 g, 2.003 mmol) and allowed to stir overnight. The 
solution was filtered through celite and concentrated in vacuo. The residue was purified via flash 
column chromatography (EtOAc: Hexanes, 27:83)  
 
PDC oxidation product (78.9 mg, 0.381 mmol) The general PDC oxidation procedure used 
compound 16 as the starting material to afford compound 17 a white solid. 
1
H NMR (300 MHz, 
CDCl3) δ 9.54 (s, 4H), 7.36 (s, 26H), 5.12 (s, 9H), 4.37 – 4.20 (m, 4H), 2.42 (s, 2H), 1.36 (d, J = 
7.3 Hz, 14H). 
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Acetal Formation for the Alanine derivative 
 
The Cbz protected Alaninal was dissolved in toluene (6.35 mL) to which ethylene glycol (0.320 
mL, 5.711 mmol) and p-toluenesulfonic acid (0.029 g, 0.152 mmol) were added. The mixture 
was refluxed overnight, concentrated under reduced pressure, and subsequently taken up in 
DCM. The mixture was washed 3 times with H2O and NaHCO3 and concentrated under reduced 
pressure. The presence of the desired product, 18, was confirmed by 
1
H NMR 
 
SPPS: Deprotection of the Fmoc and amino acid coupling procedure 
 
After the Wang resin is swelled in DMF for 3 hours and washed three times with DMF a solution 
of 20% piperidine in DMF is added and allowed to shake at 21°C for 30 minutes. The solution is 
then filtered and washed with DMF 3 times upon which 2 equivalents (based on resin 
substitution) of the protected amino acid dissolved in DMF (5 mL/ gram of resin) is added. 
HATU (2 equivalents) is subsequently added with DIPEA (4 equivalents) and the mixture is 
allowed to stir for 2.5 hours before the deprotection sequence may be run again.  
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SPPS: Global side chain deprotection and Wang resin decoupling 
 
The resin-bound polypeptide is placed in a solution (4 times the height of the swelled beads) of 
95:2.5:2.5 TFA:TES:H2O and stirred for three hours. The decoupled and deprotected product 
was removed by vacuum filtration and the product was extracted with 0 °C diethyl ether.  
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